Molecular Medicine

, Volume 13, Issue 1–2, pp 79–88 | Cite as

Phosphorylation of FAK, PI-3K, and Impaired Actin Organization in CK-positive Micrometastatic Breast Cancer Cells

  • Galatea Kallergi
  • Dimitris Mavroudis
  • Vassilis Georgoulias
  • Christos Stournaras
Research Article


Several markers have been used to detect circulating tumor cells (CTC) in the peripheral blood of patients with breast cancer. However, analysis of activated signaling kinases in CTC implicated in cellular transformation, migration, and survival has not been addressed so far. In the present study, we focused on the phenotypic profile of micrometastatic cells in peripheral blood mononuclear cells (PBMC) preparations from 45 breast cancer patients. PBMC cytospins from 28 cytokeratin (CK)-positive and 17 CK-negative samples were assessed for the expression of phosphorylated FAK (p-FAK), phosphorylated PI-3 kinase (p-PI-3K), and HER2 using confocal laser scanning microscopy. The expression of p-FAK was documented in all 28 CK-positive samples, while all 17 CK-negative samples were tested negative for p-FAK. Immunomagnetic separation using EpCAM antibody fully confirmed these findings, implying a sound correlation for the co-expression of the two molecules. Interestingly, 15 of 28 CK- and p-FAK-positive samples also expressed the HER2 oncoprotein. p-PI-3K was documented in 15 of 17 CK- and p-FAK-positive samples. Immunoblot analysis of micrometastatic cells in co-culture with PBMC confirmed the specific expression of both p-FAK and p-PI-3K. Finally, impaired actin organization was apparent in CK- and p-FAK/p-PI-3K-positive samples, comparable to that observed in MCF-7 human breast cancer cells. Our findings provide strong evidence that micrometastatic cells express activated signaling kinases, which may regulate migration mechanisms, supporting the presumption of their malignant and metastatic nature.



The European Social Fund and National recourses supported this work.


  1. 1.
    van ’t Veer LJ et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536.CrossRefGoogle Scholar
  2. 2.
    van de Vijver MJ et al. (2002) Agene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999–2009.CrossRefGoogle Scholar
  3. 3.
    Ramaswamy S, Ross KN, Lander ES, Golub TR. (2003) A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:49–54.Google Scholar
  4. 4.
    Bernards R, Weinberg RA. (2002) Aprogression puzzle. Nature 418:823CrossRefGoogle Scholar
  5. 5.
    Van’t Veer LJ, Weigelt B. (2003) Road map to metastasis. Nat. Med. 9:999–1000.CrossRefGoogle Scholar
  6. 6.
    Braun S, Harbeck N. (2001) Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention. Expert Rev. Mol. Med. 2001:1–14.Google Scholar
  7. 7.
    Pantel K et al. (2003) Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin. Cancer Res. 15:6326–6334.Google Scholar
  8. 8.
    Pantel K, Cote RJ, Fodstad O. (1999) Detection and clinical importance of micrometastatic disease. J. Natl. Cancer Inst. 91:1113–1124.CrossRefGoogle Scholar
  9. 9.
    Stathopoulou A et al. (2002) Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 20:3404–3412.CrossRefGoogle Scholar
  10. 10.
    Xenidis N et al. (2006) Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol. 24:3756–3762.CrossRefGoogle Scholar
  11. 11.
    Braun S et al. (2001) ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I–III breast cancer patients. Cancer Res. 61:1890–1895.PubMedGoogle Scholar
  12. 12.
    Gaforio JJ et al. (2003) Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int. J. Cancer 107:984–990.CrossRefGoogle Scholar
  13. 13.
    Thurm H et al. (2003) Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin. Cancer Res. 9:2598–2604PubMedGoogle Scholar
  14. 14.
    Klein CA et al. (2002). Genetic heterogeneity of single disseminated tumor cells in minimal residual cancer. Lancet 360:683–689.CrossRefGoogle Scholar
  15. 15.
    Pantel K et al. (1995) Establishment of micro-metastatic carcinoma cell lines: a novel source of tumor cell vaccines. J. Natl. Cancer Inst. 87:1162–1168.CrossRefGoogle Scholar
  16. 16.
    Solakoglu O et al. (2002) Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumours. Proc. Natl. Acad. Sci. U.S.A. 99:2246–2251.CrossRefGoogle Scholar
  17. 17.
    Pierga JY et al. (2003) Related clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer. Br. J. Cancer. 89:539–545.CrossRefGoogle Scholar
  18. 18.
    Stournaras C et al. (1996) Altered actin polymerization dynamics in various malignant cell types: evidence for differential sensitivity to cytochalasin B. Biochem. Pharmacol. 52:1339–1346CrossRefGoogle Scholar
  19. 19.
    Jordan MA, Wilson L. (1998) Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 10:123–130CrossRefGoogle Scholar
  20. 20.
    Carpenter CL. (2000) Actin cytoskeleton and cell signaling. Crit. Care Med. 28:N94–N99CrossRefGoogle Scholar
  21. 21.
    Rodriguez-Fernandez JL. (1999) Why do so many stimuli induce tyrosine phosphorylation of FAK? Bioessays 21:1069–1075.CrossRefGoogle Scholar
  22. 22.
    Jones RJ, Brunton VG, Frame MC. (2000) Adhesion-linked kinases in cancer; emphasis on src, focal adhesion kinase and PI 3-kinase. Eur. J. Cancer 36:1595–1606CrossRefGoogle Scholar
  23. 23.
    Kallergi G et al. (2003) Distinct signaling pathways regulate differential opioid effects on actin cytoskeleton in malignant MCF7 and nonmalignant MCF12A human breast epithelial cells. Exp. Cell Res. 288:94–109.CrossRefGoogle Scholar
  24. 24.
    Stathopoulou A et al. (2003) Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the Light-Cycler system. Clin. Cancer Res. 9:5145–5151.PubMedGoogle Scholar
  25. 25.
    Papakonstanti EA, Emmanouel DS, Gravanis A, Stournaras C. (2000) PLC-gamma1 signaling pathway and villin activation are involved in actin cytoskeleton reorganization induced by Na+/Pi cotransport up-regulation. Mol. Med. 6:303–318.CrossRefGoogle Scholar
  26. 26.
    Chen HC, Appeddu PA, Isoda H, Guan JL. (1996) Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J. Biol. Chem. 271:26329–26334.CrossRefGoogle Scholar
  27. 27.
    Saito Y et al. (1996) Phosphatidylinositol 3-kinase activity is required for the activation process of focal adhesion kinase by platelet-derived growth factor. Biochem. Biophys. Res. Commun. 224:23–26.CrossRefGoogle Scholar
  28. 28.
    Papakonstanti EA, Kampa M, Castanas E, Stournaras C. (2003) A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol. Endocrinol. 17:870–881.CrossRefGoogle Scholar
  29. 29.
    Bozionellou V et al. (2004) Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin. Cancer Res. 10:8185–8194.CrossRefGoogle Scholar
  30. 30.
    Koukouritaki SB et al. (1999) TNF-α induces actin cytoskeleton reorganization in glomerular epithelial cells involving tyrosine phosphorylation of paxillin and focal adhesion kinase. Mol. Med. 5:382–392.CrossRefGoogle Scholar
  31. 31.
    Schaller MD. (2001) Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim. Biophys. Acta 1540:1–21.CrossRefGoogle Scholar
  32. 32.
    Jones RJ, Brunton VG, Frame MC. (2000) Adhesion-linked kinases in cancer; emphasis on src, focal adhesion kinase and PI 3-kinase. Eur. J. Cancer 36:1595–1606.CrossRefGoogle Scholar
  33. 33.
    Tremblay L et al. (1996) Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int. J. Cancer 68:164–171.CrossRefGoogle Scholar
  34. 34.
    Pantel K et al. (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J. Natl. Cancer Inst. (Bethesda) 85:1419–1424.CrossRefGoogle Scholar
  35. 35.
    Klein CA et al. (2002) Genetic heterogeneity of single disseminated tumor cells in minimal residual cancer. Lancet 360:683–689.CrossRefGoogle Scholar
  36. 36.
    Hatzoglou A et al. (2005) Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J. Clin. Endocrinol. Metab. 90:893–903.CrossRefGoogle Scholar
  37. 37.
    Moustakas A, Stournaras C. (1999) Regulation of actin organisation by TGF-β in H-ras-transformed fibroblasts. J. Cell Sci. 112:1169–1179.PubMedGoogle Scholar
  38. 38.
    Kampa M et al. (2002) The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors, which increase PSA secretion and modify actin cytoskeleton. FASEB J. 16:1429–1431CrossRefGoogle Scholar
  39. 39.
    Coussens L et al. (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139.CrossRefGoogle Scholar
  40. 40.
    Slamon DJ et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177–182.CrossRefGoogle Scholar
  41. 41.
    Wulfing P et al. (2006) HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res. 12:1715–1720.CrossRefGoogle Scholar
  42. 42.
    Braun S et al. (2000) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J. Clin. Oncol. 18:80–86.CrossRefGoogle Scholar
  43. 43.
    Xenidis N et al. (2003) Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann. Oncol. 14:849–855.CrossRefGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2007

Authors and Affiliations

  • Galatea Kallergi
    • 1
  • Dimitris Mavroudis
    • 2
  • Vassilis Georgoulias
    • 2
  • Christos Stournaras
    • 1
  1. 1.Department of BiochemistryUniversity of Crete Medical SchoolHeraklion VoutesGreece
  2. 2.Department of Medical OncologyUniversity Hospital of HeraklionHeraklionGreece

Personalised recommendations